Single dose of metformin reduces hepatic venous pressure in portal hypertension: Study

Written By :  Dr. Nandita Mohan
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-08-06 03:30 GMT   |   Update On 2021-08-06 03:30 GMT
Advertisement

Portal hypertension is the main determinant of clinical decompensation in patients with liver cirrhosis. In preclinical data metformin lowers portal pressure, but there are no clinical data for this beneficial effect.

One study recently published in the Alimentary Pharmacology and Therapeutics Journal highlighted that a single oral metformin dose acutely reduces hepatic venous pressure gradient (HVPG) in patients with portal hypertension without affecting systemic or liver hemodynamics or inflammatory biomarkers.

Advertisement

Nikolaj Rittig and associates from the Department and Laboratories of Diabetes and Hormone diseases, Aarhus University Hospital, Aarhus, Denmark aimed to investigate the acute effects of metformin on hepatic venous pressure gradient (HVPG) and liver perfusion.

In a randomised, double-blinded study design, the authors investigated a total of 32 patients with cirrhosis before and 90 minutes after ingestion of 1000-mg metformin (n = 16) or placebo (n = 16). Liver vein catherisation was performed to evaluate hepatic venous pressure gradient and indocyanine green (ICG) infusion for investigation of hepatic blood flow.

The following findings were identified-

  1. The mean relative change in hepatic venous pressure gradient was −16% (95% CI: −28% to −4%) in the metformin group compared with 4% (95% CI: −6% to 14%) in the placebo group (time × group interaction, P = 0.008).
  2. In patients with baseline hepatic venous pressure gradient ≥12 mm Hg clinically significant improvements in hepatic venous pressure gradient (HVPG <12 mm Hg or a >20% reduction in HVPG) were observed in 46% (6/13) of metformin-treated and in 8% (1/13) of placebo-treated patients (P = 0.07).
  3. There were no changes or differences in systemic blood pressure, heart rate, hepatic plasma and blood flow, hepatic indocyanine green clearance, hepatic O2 uptake or inflammation markers between groups.

Hence, the authors concluded that "a single oral metformin dose acutely reduces HVPG in patients with portal hypertension without affecting systemic or liver hemodynamics or inflammatory biomarkers."

This offers a promising perspective of a safe and inexpensive treatment option that should be investigated in larger-scale clinical studies with long-term outcomes in patients with cirrhosis and portal hypertension, they further added.

https://doi.org/10.1111/apt.16460



Tags:    
Article Source : Alimentary Pharmacology and Therapeutics Journal

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News